FIELD: biotechnology.
SUBSTANCE: isolated monoclonal antibodies, which specifically bind to EGFL6, and conjugates including them are proposed. Nucleic acids, expression vectors, and host cells for the production of the specified antibodies are also proposed. Antibodies, according to the invention, can be used for the detection or therapeutic treatment of EGFL6-positive malignant tumor.
EFFECT: invention provides for high affinity of binding and effective inhibition of EGFL6 activity and cancer cell growth.
38 cl, 12 dwg, 3 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTI-C5 ANTIBODIES AND THEIR USE | 2018 |
|
RU2774716C2 |
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTIBODIES AGAINST CXCR5, THEIR COMPOSITIONS AND USE | 2018 |
|
RU2798422C2 |
| THERAPEUTIC AGENTS AND METHODS FOR THE TREATMENT OF TLR2-MEDIATED DISEASES AND DISORDERS | 2019 |
|
RU2791022C2 |
| TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS USING CROSSOVER FORMAT WITH DOUBLE VARIABLE DOMAIN (CODV) FOR TREATING INFECTION CAUSED BY HIV | 2020 |
|
RU2820164C2 |
| TREATMENT OF MALIGNANT NEOPLASM USING HUMANIZED CHIMERIC ANTIGEN RECEPTOR AGAINST BCMA | 2015 |
|
RU2751660C2 |
| CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
| ANTI-INTERFERON BETA ANTIBODIES AND THEIR USE | 2017 |
|
RU2750454C2 |
